CorMedix Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	214.3	43.47	-	0.07	0.19	0.24
Revenue Growth (YoY)	1647.67%	-	-	-65.74%	-20.19%	-15.54%
Cost of Revenue	12.2	3.19	-	0	0.15	0.2
Gross Profit	202.1	40.28	-	0.06	0.04	0.03
Selling, General & Admin	82.06	58.7	35.8	20.01	16.35	13.88
Research & Development	12.46	3.94	13.16	10.68	13.13	13.38
Operating Expenses	98.15	62.64	48.96	30.69	29.48	27.26
Operating Income	103.95	-22.36	-48.96	-30.62	-29.44	-27.22
Interest Expense	-0.97	-0.04	-0.03	-0.03	-0.02	-0.03
Interest & Investment Income	3.47	2.58	2.68	0.33	0.01	0.12
Currency Exchange Gain (Loss)	-0.12	-0.03	-0.03	0.04	-0.02	-0.06
Other Non Operating Income (Expenses)	0.02	0.52	-	-	-	-
EBT Excluding Unusual Items	106.34	-19.32	-46.34	-30.29	-29.46	-27.2
Other Unusual Items	-2.4	-	-	-	-	-
Pretax Income	107.03	-19.32	-46.34	-30.29	-29.46	-27.2
Income Tax Expense	-55.47	-1.39	-	-0.59	-1.25	-5.17
Net Income	162.5	-17.93	-46.34	-29.7	-28.21	-22.03
Net Income to Common	162.5	-17.93	-46.34	-29.7	-28.21	-22.03
Shares Outstanding (Basic)	68	59	51	40	38	29
Shares Outstanding (Diluted)	72	59	51	40	38	29
Shares Change (YoY)	24.69%	15.65%	26.39%	6.93%	31.87%	18.26%
EPS (Basic)	2.40	-0.30	-0.91	-0.74	-0.75	-0.77
EPS (Diluted)	2.25	-0.30	-0.91	-0.74	-0.75	-0.77
Free Cash Flow	74.42	-50.73	-38.74	-24.58	-22.58	-22.08
Free Cash Flow Per Share	1.03	-0.86	-0.76	-0.61	-0.60	-0.77
Gross Margin	94.31%	92.66%	-	94.29%	22.00%	14.37%
Operating Margin	48.51%	-51.43%	-	-46819.91%	-15417.51%	-11378.44%
Profit Margin	75.83%	-41.24%	-	-45409.90%	-14774.70%	-9207.70%
Free Cash Flow Margin	34.73%	-116.70%	-	-37573.53%	-11826.24%	-9229.69%
EBITDA	108.2	-22.05	-48.89	-30.54	-29.38	-27.09
EBITDA Margin	50.49%	-50.71%	-	-	-	-
D&A For EBITDA	4.25	0.31	0.07	0.08	0.06	0.13
EBIT	103.95	-22.36	-48.96	-30.62	-29.44	-27.22
EBIT Margin	48.51%	-51.43%	-	-	-	-

Updated Nov 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q